Theresa Grover
Concepts (345)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intensive Care Units, Neonatal | 36 | 2026 | 279 | 4.100 |
Why?
| | Hernias, Diaphragmatic, Congenital | 18 | 2026 | 219 | 3.980 |
Why?
| | Extracorporeal Membrane Oxygenation | 9 | 2026 | 382 | 1.710 |
Why?
| | Infant, Newborn | 61 | 2026 | 6424 | 1.610 |
Why?
| | Infant, Premature | 14 | 2025 | 611 | 1.530 |
Why?
| | Catheterization, Central Venous | 6 | 2025 | 122 | 1.350 |
Why?
| | Cross Infection | 3 | 2025 | 262 | 1.300 |
Why?
| | Bacterial Infections | 2 | 2025 | 246 | 1.250 |
Why?
| | Bronchopulmonary Dysplasia | 10 | 2024 | 410 | 1.090 |
Why?
| | Central Venous Catheters | 5 | 2025 | 52 | 1.030 |
Why?
| | Urinary Tract Infections | 4 | 2025 | 202 | 1.030 |
Why?
| | Pulmonary Circulation | 15 | 2011 | 430 | 0.910 |
Why?
| | Gestational Age | 17 | 2025 | 975 | 0.900 |
Why?
| | Length of Stay | 12 | 2026 | 1335 | 0.880 |
Why?
| | Enteral Nutrition | 4 | 2025 | 216 | 0.850 |
Why?
| | Mycoses | 1 | 2025 | 88 | 0.850 |
Why?
| | Catheter-Related Infections | 4 | 2017 | 94 | 0.750 |
Why?
| | Gastroschisis | 4 | 2025 | 32 | 0.700 |
Why?
| | Quality Improvement | 9 | 2024 | 1285 | 0.600 |
Why?
| | Catheterization, Peripheral | 1 | 2021 | 117 | 0.600 |
Why?
| | Hypertension, Pulmonary | 11 | 2021 | 1980 | 0.600 |
Why?
| | Bottle Feeding | 1 | 2019 | 19 | 0.590 |
Why?
| | Fetus | 14 | 2020 | 803 | 0.580 |
Why?
| | Infant | 27 | 2026 | 10022 | 0.570 |
Why?
| | Infant Formula | 1 | 2019 | 71 | 0.560 |
Why?
| | Retrospective Studies | 33 | 2026 | 17009 | 0.560 |
Why?
| | Hospitals, Pediatric | 6 | 2025 | 555 | 0.560 |
Why?
| | Vascular Endothelial Growth Factor A | 6 | 2007 | 557 | 0.550 |
Why?
| | Bacteremia | 4 | 2024 | 221 | 0.530 |
Why?
| | Practice Guidelines as Topic | 6 | 2024 | 1559 | 0.530 |
Why?
| | Postoperative Complications | 5 | 2025 | 2916 | 0.520 |
Why?
| | Lung | 10 | 2011 | 4108 | 0.510 |
Why?
| | Parenteral Nutrition, Total | 1 | 2017 | 30 | 0.510 |
Why?
| | Vasodilation | 11 | 2011 | 522 | 0.490 |
Why?
| | Weight Gain | 2 | 2017 | 556 | 0.480 |
Why?
| | Sheep | 20 | 2011 | 880 | 0.480 |
Why?
| | Intensive Care, Neonatal | 4 | 2020 | 42 | 0.450 |
Why?
| | High-Frequency Ventilation | 1 | 2015 | 45 | 0.450 |
Why?
| | Infant, Premature, Diseases | 2 | 2024 | 111 | 0.430 |
Why?
| | Intersectoral Collaboration | 1 | 2015 | 62 | 0.430 |
Why?
| | Developmental Disabilities | 1 | 2018 | 281 | 0.430 |
Why?
| | Patient Education as Topic | 1 | 2019 | 777 | 0.400 |
Why?
| | Nitric Oxide Synthase | 9 | 2006 | 235 | 0.400 |
Why?
| | Tracheostomy | 3 | 2024 | 142 | 0.390 |
Why?
| | Humans | 64 | 2026 | 144261 | 0.380 |
Why?
| | Endothelial Growth Factors | 2 | 2002 | 64 | 0.380 |
Why?
| | Lymphokines | 2 | 2002 | 130 | 0.370 |
Why?
| | Anti-Bacterial Agents | 4 | 2024 | 1906 | 0.370 |
Why?
| | Female | 54 | 2026 | 77976 | 0.370 |
Why?
| | Hospitalization | 3 | 2021 | 2424 | 0.360 |
Why?
| | Nitric Oxide | 10 | 2011 | 897 | 0.350 |
Why?
| | Patient Discharge | 6 | 2025 | 977 | 0.350 |
Why?
| | Surgical Procedures, Operative | 1 | 2014 | 268 | 0.340 |
Why?
| | Intercellular Signaling Peptides and Proteins | 2 | 2002 | 381 | 0.330 |
Why?
| | Pulmonary Artery | 11 | 2011 | 1134 | 0.320 |
Why?
| | Parents | 1 | 2019 | 1401 | 0.310 |
Why?
| | Intubation, Intratracheal | 2 | 2024 | 320 | 0.310 |
Why?
| | Respiration, Artificial | 6 | 2026 | 707 | 0.300 |
Why?
| | Male | 33 | 2026 | 72035 | 0.300 |
Why?
| | Databases, Factual | 7 | 2025 | 1484 | 0.290 |
Why?
| | Hospital Mortality | 4 | 2026 | 1027 | 0.290 |
Why?
| | Persistent Fetal Circulation Syndrome | 2 | 2011 | 138 | 0.290 |
Why?
| | Anesthesia | 2 | 2023 | 257 | 0.290 |
Why?
| | Pregnancy | 23 | 2021 | 7180 | 0.280 |
Why?
| | Survival Rate | 4 | 2018 | 2088 | 0.270 |
Why?
| | Patient Care Bundles | 2 | 2019 | 28 | 0.260 |
Why?
| | Lung Diseases | 1 | 2014 | 787 | 0.260 |
Why?
| | Infant Mortality | 2 | 2026 | 123 | 0.250 |
Why?
| | Nitric Oxide Synthase Type III | 6 | 2007 | 204 | 0.250 |
Why?
| | Guideline Adherence | 4 | 2025 | 586 | 0.250 |
Why?
| | Fibrin | 1 | 2007 | 91 | 0.240 |
Why?
| | Fetal Diseases | 3 | 2004 | 191 | 0.240 |
Why?
| | Intestinal Atresia | 1 | 2025 | 17 | 0.230 |
Why?
| | Urea Cycle Disorders, Inborn | 1 | 2026 | 26 | 0.230 |
Why?
| | Hernia, Diaphragmatic | 1 | 2026 | 67 | 0.230 |
Why?
| | Jejunum | 1 | 2025 | 35 | 0.230 |
Why?
| | Hospitals, High-Volume | 1 | 2026 | 49 | 0.230 |
Why?
| | Guanylate Cyclase | 4 | 2011 | 39 | 0.230 |
Why?
| | Multivariate Analysis | 5 | 2025 | 1533 | 0.230 |
Why?
| | Logistic Models | 6 | 2025 | 2104 | 0.230 |
Why?
| | Heart Defects, Congenital | 2 | 2026 | 913 | 0.230 |
Why?
| | Pulmonary Alveoli | 2 | 2005 | 383 | 0.230 |
Why?
| | Infection Control | 2 | 2017 | 171 | 0.220 |
Why?
| | Ileum | 1 | 2025 | 111 | 0.220 |
Why?
| | Bradycardia | 2 | 2024 | 59 | 0.220 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2007 | 297 | 0.220 |
Why?
| | Anastomotic Leak | 1 | 2024 | 44 | 0.210 |
Why?
| | Ductus Arteriosus, Patent | 1 | 2025 | 50 | 0.210 |
Why?
| | Ventilator Weaning | 1 | 2024 | 39 | 0.210 |
Why?
| | Consensus | 2 | 2024 | 488 | 0.210 |
Why?
| | Esophageal Atresia | 1 | 2024 | 30 | 0.210 |
Why?
| | Device Removal | 1 | 2025 | 142 | 0.210 |
Why?
| | North America | 1 | 2025 | 310 | 0.210 |
Why?
| | Stenosis, Pulmonary Vein | 1 | 2024 | 19 | 0.210 |
Why?
| | Tracheoesophageal Fistula | 1 | 2024 | 38 | 0.210 |
Why?
| | Blood Culture | 1 | 2024 | 25 | 0.210 |
Why?
| | Critical Pathways | 1 | 2025 | 106 | 0.210 |
Why?
| | Cyclic GMP | 4 | 2011 | 92 | 0.200 |
Why?
| | Clinical Protocols | 1 | 2025 | 282 | 0.200 |
Why?
| | Severity of Illness Index | 6 | 2026 | 2917 | 0.200 |
Why?
| | Laryngoscopy | 1 | 2024 | 117 | 0.200 |
Why?
| | Ductus Arteriosus | 6 | 2008 | 72 | 0.190 |
Why?
| | Neovascularization, Pathologic | 1 | 2004 | 286 | 0.190 |
Why?
| | Delphi Technique | 1 | 2024 | 329 | 0.180 |
Why?
| | Hemangioendothelioma | 1 | 2002 | 13 | 0.180 |
Why?
| | Infant, Newborn, Diseases | 1 | 2023 | 113 | 0.180 |
Why?
| | Infant, Small for Gestational Age | 2 | 2025 | 109 | 0.170 |
Why?
| | Time Factors | 7 | 2024 | 7155 | 0.170 |
Why?
| | Uterus | 1 | 2002 | 226 | 0.170 |
Why?
| | Patient Handoff | 1 | 2021 | 42 | 0.170 |
Why?
| | Retrognathia | 1 | 2020 | 4 | 0.170 |
Why?
| | Hepatitis B Vaccines | 1 | 2021 | 43 | 0.170 |
Why?
| | Animals, Newborn | 7 | 2009 | 901 | 0.160 |
Why?
| | Micrognathism | 1 | 2020 | 19 | 0.160 |
Why?
| | Neuromuscular Blockade | 1 | 2021 | 51 | 0.160 |
Why?
| | Hepatitis B | 1 | 2021 | 66 | 0.160 |
Why?
| | Betamethasone | 1 | 2000 | 21 | 0.160 |
Why?
| | Benzoates | 2 | 2011 | 50 | 0.160 |
Why?
| | Social Determinants of Health | 1 | 2024 | 299 | 0.160 |
Why?
| | Analgesia | 1 | 2021 | 105 | 0.160 |
Why?
| | Vascular Resistance | 6 | 2011 | 366 | 0.160 |
Why?
| | Ventricular Septum | 1 | 2019 | 8 | 0.150 |
Why?
| | Carbon Monoxide | 1 | 2000 | 82 | 0.150 |
Why?
| | Incidence | 2 | 2018 | 2870 | 0.150 |
Why?
| | Hypothermia | 1 | 2020 | 52 | 0.150 |
Why?
| | United States | 7 | 2025 | 15876 | 0.150 |
Why?
| | Cooperative Behavior | 3 | 2017 | 462 | 0.150 |
Why?
| | Food, Fortified | 1 | 2019 | 44 | 0.150 |
Why?
| | Geographic Mapping | 1 | 2019 | 29 | 0.140 |
Why?
| | Neonatology | 1 | 2019 | 28 | 0.140 |
Why?
| | Blood Pressure | 5 | 2019 | 1759 | 0.140 |
Why?
| | Airway Obstruction | 1 | 2020 | 162 | 0.140 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 2 | 2011 | 209 | 0.140 |
Why?
| | Endothelium, Vascular | 1 | 2005 | 963 | 0.140 |
Why?
| | Recombinant Proteins | 4 | 2005 | 1367 | 0.140 |
Why?
| | Animals | 22 | 2011 | 38030 | 0.140 |
Why?
| | Community-Acquired Infections | 1 | 2020 | 174 | 0.140 |
Why?
| | Respiratory Insufficiency | 1 | 2021 | 326 | 0.140 |
Why?
| | Housing | 1 | 2019 | 144 | 0.130 |
Why?
| | Echocardiography, Doppler | 1 | 2018 | 115 | 0.130 |
Why?
| | Perioperative Care | 1 | 2020 | 230 | 0.130 |
Why?
| | Odds Ratio | 2 | 2020 | 1072 | 0.130 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2020 | 340 | 0.130 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2017 | 73 | 0.120 |
Why?
| | Continuity of Patient Care | 1 | 2019 | 287 | 0.120 |
Why?
| | Premature Birth | 1 | 2020 | 380 | 0.120 |
Why?
| | Heart Arrest | 1 | 2020 | 407 | 0.120 |
Why?
| | Echocardiography | 1 | 2019 | 647 | 0.120 |
Why?
| | Infant, Extremely Premature | 1 | 2017 | 67 | 0.120 |
Why?
| | Patient Readmission | 2 | 2019 | 756 | 0.120 |
Why?
| | Disease Models, Animal | 6 | 2011 | 4556 | 0.120 |
Why?
| | Patient Transfer | 1 | 2019 | 206 | 0.120 |
Why?
| | Hemodynamics | 6 | 2011 | 1119 | 0.120 |
Why?
| | Glucocorticoids | 1 | 2000 | 533 | 0.120 |
Why?
| | Child | 8 | 2023 | 22537 | 0.120 |
Why?
| | Antimicrobial Stewardship | 1 | 2018 | 129 | 0.120 |
Why?
| | Risk Adjustment | 1 | 2016 | 85 | 0.110 |
Why?
| | Vasoconstriction | 2 | 2008 | 217 | 0.110 |
Why?
| | Clinical Nursing Research | 1 | 2015 | 13 | 0.110 |
Why?
| | Ligation | 3 | 2025 | 92 | 0.110 |
Why?
| | Liver Neoplasms | 1 | 2002 | 780 | 0.110 |
Why?
| | Communication | 1 | 2021 | 961 | 0.110 |
Why?
| | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 3 | 2011 | 28 | 0.110 |
Why?
| | Enterocolitis, Necrotizing | 2 | 2024 | 41 | 0.100 |
Why?
| | Enzyme Activation | 3 | 2005 | 765 | 0.100 |
Why?
| | Nitroarginine | 5 | 2006 | 57 | 0.100 |
Why?
| | rho-Associated Kinases | 3 | 2011 | 83 | 0.100 |
Why?
| | Pregnancy Complications, Cardiovascular | 2 | 2004 | 83 | 0.100 |
Why?
| | Premedication | 2 | 2024 | 42 | 0.100 |
Why?
| | Program Evaluation | 1 | 2017 | 946 | 0.100 |
Why?
| | Vascular Endothelial Growth Factors | 2 | 2002 | 80 | 0.090 |
Why?
| | Linear Models | 2 | 2025 | 850 | 0.090 |
Why?
| | Heart Septal Defects, Ventricular | 2 | 2026 | 46 | 0.090 |
Why?
| | Administration, Inhalation | 2 | 2007 | 574 | 0.090 |
Why?
| | Mothers | 1 | 2019 | 774 | 0.090 |
Why?
| | Isoenzymes | 2 | 2011 | 299 | 0.090 |
Why?
| | Vasodilator Agents | 2 | 2011 | 331 | 0.090 |
Why?
| | Pneumonia | 1 | 2018 | 630 | 0.090 |
Why?
| | Apgar Score | 2 | 2023 | 20 | 0.090 |
Why?
| | Enzyme Inhibitors | 5 | 2009 | 824 | 0.080 |
Why?
| | Leadership | 1 | 2015 | 408 | 0.080 |
Why?
| | Health Services Accessibility | 1 | 2019 | 1091 | 0.080 |
Why?
| | Sulfones | 3 | 2005 | 127 | 0.080 |
Why?
| | Pyridines | 4 | 2011 | 605 | 0.080 |
Why?
| | Infant, Low Birth Weight | 2 | 2022 | 153 | 0.080 |
Why?
| | Chronic Disease | 2 | 2014 | 1812 | 0.080 |
Why?
| | Prevalence | 3 | 2024 | 2815 | 0.080 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2011 | 266 | 0.080 |
Why?
| | Treatment Outcome | 5 | 2025 | 11643 | 0.070 |
Why?
| | Serotonin | 1 | 2011 | 293 | 0.070 |
Why?
| | Risk Factors | 4 | 2025 | 10699 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 1 | 2022 | 3857 | 0.070 |
Why?
| | Pulmonary Wedge Pressure | 2 | 2009 | 67 | 0.070 |
Why?
| | Amides | 2 | 2006 | 101 | 0.070 |
Why?
| | Cohort Studies | 4 | 2021 | 5935 | 0.070 |
Why?
| | Muscle, Smooth, Vascular | 3 | 2009 | 452 | 0.070 |
Why?
| | Immunohistochemistry | 2 | 2002 | 1715 | 0.070 |
Why?
| | Procollagen-Proline Dioxygenase | 1 | 2007 | 27 | 0.060 |
Why?
| | Estradiol | 2 | 2001 | 533 | 0.060 |
Why?
| | Immediate-Early Proteins | 1 | 2007 | 48 | 0.060 |
Why?
| | Cardiovascular Agents | 1 | 2008 | 163 | 0.060 |
Why?
| | Oxadiazoles | 3 | 2011 | 37 | 0.060 |
Why?
| | Comorbidity | 2 | 2024 | 1646 | 0.060 |
Why?
| | Case-Control Studies | 2 | 2024 | 3592 | 0.060 |
Why?
| | Hospitals, Low-Volume | 1 | 2026 | 25 | 0.060 |
Why?
| | Selenium | 1 | 2025 | 49 | 0.060 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2005 | 35 | 0.060 |
Why?
| | Renal Replacement Therapy | 1 | 2026 | 99 | 0.060 |
Why?
| | Protein Kinase Inhibitors | 2 | 2008 | 968 | 0.050 |
Why?
| | Thoracoscopy | 1 | 2024 | 62 | 0.050 |
Why?
| | Chylothorax | 1 | 2024 | 20 | 0.050 |
Why?
| | Abnormalities, Multiple | 1 | 2026 | 197 | 0.050 |
Why?
| | Antibiotic Prophylaxis | 1 | 2025 | 129 | 0.050 |
Why?
| | Hyperoxia | 1 | 2005 | 99 | 0.050 |
Why?
| | Pyrazoles | 2 | 2005 | 509 | 0.050 |
Why?
| | Anastomosis, Surgical | 1 | 2024 | 157 | 0.050 |
Why?
| | Birth Weight | 1 | 2007 | 522 | 0.050 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2024 | 88 | 0.050 |
Why?
| | Body Weight | 2 | 2005 | 976 | 0.050 |
Why?
| | Noninvasive Ventilation | 1 | 2024 | 62 | 0.050 |
Why?
| | Video Recording | 1 | 2024 | 211 | 0.050 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2006 | 459 | 0.050 |
Why?
| | Parenteral Nutrition | 1 | 2024 | 105 | 0.050 |
Why?
| | Homeodomain Proteins | 1 | 2007 | 523 | 0.050 |
Why?
| | Chromones | 1 | 2002 | 42 | 0.050 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2003 | 90 | 0.050 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2002 | 109 | 0.050 |
Why?
| | Acetaminophen | 1 | 2025 | 264 | 0.050 |
Why?
| | Morpholines | 1 | 2002 | 128 | 0.050 |
Why?
| | Clinical Trials as Topic | 1 | 2007 | 1050 | 0.040 |
Why?
| | Airway Extubation | 1 | 2022 | 60 | 0.040 |
Why?
| | Oligonucleotides | 1 | 2002 | 149 | 0.040 |
Why?
| | Drug Administration Schedule | 2 | 2001 | 778 | 0.040 |
Why?
| | Gastroesophageal Reflux | 1 | 2024 | 236 | 0.040 |
Why?
| | Prostaglandins | 1 | 2001 | 94 | 0.040 |
Why?
| | Estrogen Antagonists | 1 | 2001 | 48 | 0.040 |
Why?
| | Artifacts | 1 | 2022 | 139 | 0.040 |
Why?
| | Respiration | 1 | 2022 | 206 | 0.040 |
Why?
| | Cardiac Catheterization | 1 | 2025 | 557 | 0.040 |
Why?
| | Soluble Guanylyl Cyclase | 2 | 2011 | 16 | 0.040 |
Why?
| | Image Enhancement | 1 | 2022 | 199 | 0.040 |
Why?
| | Piperazines | 3 | 2011 | 380 | 0.040 |
Why?
| | Postoperative Period | 1 | 2021 | 353 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2011 | 2026 | 0.040 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2002 | 379 | 0.040 |
Why?
| | Protoporphyrins | 1 | 2000 | 14 | 0.040 |
Why?
| | Injections, Intra-Arterial | 1 | 2000 | 26 | 0.040 |
Why?
| | Prognosis | 2 | 2019 | 4278 | 0.040 |
Why?
| | Epinephrine | 1 | 2020 | 155 | 0.040 |
Why?
| | Quinoxalines | 2 | 2011 | 65 | 0.040 |
Why?
| | Perioperative Period | 1 | 2020 | 71 | 0.040 |
Why?
| | Benzodiazepines | 1 | 2021 | 165 | 0.040 |
Why?
| | Injections, Intramuscular | 1 | 2000 | 141 | 0.040 |
Why?
| | Airway Management | 1 | 2020 | 79 | 0.040 |
Why?
| | Proteus | 1 | 2019 | 6 | 0.040 |
Why?
| | Enterobacter | 1 | 2019 | 8 | 0.040 |
Why?
| | Pain Management | 1 | 2023 | 405 | 0.040 |
Why?
| | DNA-Binding Proteins | 1 | 2007 | 1497 | 0.040 |
Why?
| | Transportation of Patients | 1 | 2020 | 68 | 0.040 |
Why?
| | Colorado | 2 | 2020 | 4562 | 0.040 |
Why?
| | Aftercare | 1 | 2021 | 220 | 0.040 |
Why?
| | Body Temperature Regulation | 1 | 2020 | 107 | 0.040 |
Why?
| | Body Temperature | 1 | 2020 | 228 | 0.040 |
Why?
| | Hypnotics and Sedatives | 1 | 2021 | 214 | 0.040 |
Why?
| | Contrast Media | 1 | 2022 | 486 | 0.040 |
Why?
| | RNA, Messenger | 1 | 2007 | 2829 | 0.040 |
Why?
| | Reference Values | 1 | 2000 | 797 | 0.040 |
Why?
| | Benchmarking | 1 | 2020 | 188 | 0.040 |
Why?
| | Blood Vessels | 1 | 2000 | 171 | 0.030 |
Why?
| | Ultrasonography, Prenatal | 1 | 2020 | 294 | 0.030 |
Why?
| | Receptors, Estrogen | 1 | 2001 | 457 | 0.030 |
Why?
| | Surgical Mesh | 1 | 2018 | 50 | 0.030 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2020 | 187 | 0.030 |
Why?
| | Cesarean Section | 1 | 2000 | 224 | 0.030 |
Why?
| | Operating Rooms | 1 | 2020 | 146 | 0.030 |
Why?
| | Imaging, Three-Dimensional | 1 | 2022 | 582 | 0.030 |
Why?
| | Sterilization | 1 | 2017 | 24 | 0.030 |
Why?
| | Program Development | 1 | 2020 | 369 | 0.030 |
Why?
| | Drug Utilization | 1 | 2018 | 166 | 0.030 |
Why?
| | Congenital Abnormalities | 1 | 2018 | 104 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2002 | 1487 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2002 | 905 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2018 | 561 | 0.030 |
Why?
| | Risk Assessment | 2 | 2018 | 3637 | 0.030 |
Why?
| | Acetylcholine | 2 | 2009 | 204 | 0.030 |
Why?
| | Regression Analysis | 1 | 2018 | 998 | 0.030 |
Why?
| | Patient Care Team | 1 | 2021 | 686 | 0.030 |
Why?
| | 3',5'-Cyclic-GMP Phosphodiesterases | 2 | 2005 | 17 | 0.030 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 2 | 2005 | 23 | 0.030 |
Why?
| | Sildenafil Citrate | 2 | 2005 | 60 | 0.030 |
Why?
| | Staphylococcus aureus | 1 | 2019 | 454 | 0.030 |
Why?
| | Burns | 1 | 2020 | 376 | 0.030 |
Why?
| | Escherichia coli | 1 | 2019 | 852 | 0.030 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2001 | 674 | 0.030 |
Why?
| | Purines | 2 | 2005 | 187 | 0.030 |
Why?
| | Survival Analysis | 1 | 2017 | 1382 | 0.020 |
Why?
| | Cells, Cultured | 2 | 2011 | 4146 | 0.020 |
Why?
| | Vaccination | 1 | 2021 | 1422 | 0.020 |
Why?
| | Analgesics, Opioid | 1 | 2021 | 1131 | 0.020 |
Why?
| | Ketanserin | 1 | 2011 | 12 | 0.020 |
Why?
| | Serotonin 5-HT2 Receptor Antagonists | 1 | 2011 | 10 | 0.020 |
Why?
| | Hysterotomy | 1 | 2011 | 9 | 0.020 |
Why?
| | Sertraline | 1 | 2011 | 27 | 0.020 |
Why?
| | Receptors, Serotonin | 1 | 2011 | 35 | 0.020 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 2 | 2001 | 74 | 0.020 |
Why?
| | Nitroprusside | 1 | 2011 | 72 | 0.020 |
Why?
| | Fluoxetine | 1 | 2011 | 54 | 0.020 |
Why?
| | Hypertrophy, Right Ventricular | 2 | 2003 | 150 | 0.020 |
Why?
| | Kidney | 1 | 2018 | 1495 | 0.020 |
Why?
| | Adrenal Cortex Hormones | 1 | 2013 | 478 | 0.020 |
Why?
| | Hydrogen Peroxide | 1 | 2011 | 336 | 0.020 |
Why?
| | Prospective Studies | 1 | 2021 | 7970 | 0.020 |
Why?
| | Constriction | 1 | 2008 | 47 | 0.020 |
Why?
| | Indoles | 1 | 2011 | 501 | 0.020 |
Why?
| | Signal Transduction | 3 | 2006 | 5221 | 0.020 |
Why?
| | Child, Preschool | 1 | 2022 | 11774 | 0.020 |
Why?
| | Regional Blood Flow | 1 | 2008 | 512 | 0.010 |
Why?
| | Phosphoric Diester Hydrolases | 1 | 2004 | 53 | 0.010 |
Why?
| | Organ Size | 1 | 2005 | 462 | 0.010 |
Why?
| | Heart Atria | 1 | 2004 | 144 | 0.010 |
Why?
| | Drug Combinations | 1 | 2005 | 390 | 0.010 |
Why?
| | Neovascularization, Physiologic | 1 | 2005 | 194 | 0.010 |
Why?
| | Blood Flow Velocity | 1 | 2004 | 413 | 0.010 |
Why?
| | Receptor, Platelet-Derived Growth Factor beta | 1 | 2003 | 31 | 0.010 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2003 | 54 | 0.010 |
Why?
| | Meclofenamic Acid | 1 | 2001 | 9 | 0.010 |
Why?
| | 8-Bromo Cyclic Adenosine Monophosphate | 1 | 2001 | 20 | 0.010 |
Why?
| | Aorta | 1 | 2004 | 429 | 0.010 |
Why?
| | Cyclooxygenase 1 | 1 | 2001 | 26 | 0.010 |
Why?
| | Infusions, Intra-Arterial | 1 | 2001 | 61 | 0.010 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2001 | 81 | 0.010 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2001 | 66 | 0.010 |
Why?
| | Pulmonary Ventilation | 1 | 2001 | 83 | 0.010 |
Why?
| | Cyclooxygenase 2 | 1 | 2001 | 165 | 0.010 |
Why?
| | Organ Specificity | 1 | 2001 | 312 | 0.010 |
Why?
| | Ligands | 1 | 2003 | 673 | 0.010 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2001 | 162 | 0.010 |
Why?
| | Drug Interactions | 1 | 2001 | 397 | 0.010 |
Why?
| | Physical Stimulation | 1 | 2000 | 68 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2005 | 2525 | 0.010 |
Why?
| | Stress, Mechanical | 1 | 2001 | 494 | 0.010 |
Why?
| | Muscle, Smooth | 1 | 2000 | 151 | 0.010 |
Why?
| | Blotting, Western | 1 | 2001 | 1187 | 0.010 |
Why?
| | Gene Expression | 1 | 2003 | 1487 | 0.010 |
Why?
| | Rats | 1 | 2005 | 5592 | 0.010 |
Why?
|
|
Grover's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|